 HIGHLANDS RANCH, Colo., May 11, 2021 GLOBE NEWSWIRE -- Vivos Therapeutics, Inc. Nasdaq: VVOS Vivos, a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea OSA, today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock, at a public offering price of 6.00 per share. 